Methods of use for car t cells

Abstract

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

1 .- 20 . (canceled) 
     
     
         21 . A nucleic acid encoding a chimeric antigen receptor (CAR) comprising an anti-fluorescein scFv, wherein the nucleic acid comprises a first polynucleotide having at least 95% sequence identity to residues 67-2118 of SEQ ID NO:1, or 95% sequence identity to residues 67-2127 of SEQ ID NO: 4. 
     
     
         22 . The nucleic acid of  claim 21 , wherein the first polynucleotide has at least 95% sequence identity to residues 67-2118 of SEQ ID NO:1. 
     
     
         23 . The nucleic acid of  claim 21 , wherein the first polynucleotide has at least 95% sequence identity to residues 67-2127 of SEQ ID NO:4. 
     
     
         24 . The nucleic acid of  claim 21 , further comprising a second polynucleotide encoding a cell surface selectable marker. 
     
     
         25 . The nucleic acid of  claim 24 , wherein the cell surface selectable marker comprises a truncated EGFR (EGFRt) polypeptide. 
     
     
         26 . The nucleic acid of  claim 24 , wherein the second polynucleotide has at least 95% sequence identity to residues 2119-3198 of SEQ ID NO:1, or to residues 2128-3207 of SEQ ID NO: 4. 
     
     
         27 . The nucleic acid of  claim 21 , further comprising a third polynucleotide encoding a signal peptide. 
     
     
         28 . The nucleic acid of  claim 27 , wherein the third polynucleotide has at least 95% sequence identity to residues 1-66 of SEQ ID NO:1, or 95% sequence identity to residues 1-66 of SEQ ID NO: 4. 
     
     
         29 . A polypeptide encoded by the nucleic acid of  claim 21 . 
     
     
         30 . The polypeptide of  claim 29 , wherein the polypeptide comprises or consists of humanized, or human amino acid sequences. 
     
     
         31 . A vector comprising the nucleic acid of  claim 21 . 
     
     
         32 . The vector of  claim 31 , wherein the vector is a lentiviral vector. 
     
     
         33 . A cell comprising the nucleic acid of  claim 21 . 
     
     
         34 . The cell of  claim 33 , wherein the cell is a T lymphocyte or cytotoxic T lymphocyte. 
     
     
         35 . A pharmaceutical composition comprising the cell of  claim 33  and a pharmaceutically acceptable excipient. 
     
     
         36 . A method of ameliorating or treating a folate receptor expressing cancer in a patient comprising:
 labeling the cancer in said patient with a small molecule comprising folate linked to a fluorescein isothiocyanate (FITC) moiety; and   administering to the patient the cell of  claim 33 .   
     
     
         37 . The method of  claim 36 , wherein the cell is a T lymphocyte or cytotoxic T lymphocyte. 
     
     
         38 . The method of  claim 36 , wherein the cell is administered before labeling the cancer. 
     
     
         39 . The method of  claim 36 , wherein the cell is autologous to the subject.